🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

It was a pleasure to present our NasirLab work highlighting cardiovascular risk in cancer patients at #EpiLifestyle23 this past week. Grateful to Khurram Nasir for the mentorship.

#Online in JACC Journals today! Analyses from our abstract presented at the virtual #ACC23 show that patients with STEMI treated with ARNIs showed: ✅ ⬇️hospitalization for HF ✅ improvement in echocardiographic parameters ✅ ⬇️progression of LV remodeling #ACC2023

Don't delay. Fight clinical inertia. Start 4 pillars in eligible patients. Quickly. Time to consider the "time to #quadtherapy" performance measure for #HFrEF Izza Shahid Gregg Fonarow MD Duke Clinical Research Institute Journal of Cardiac Failure Javed Butler Robert Mentz, MD Anu Lala-Trindade Andrew J Sauer MD onlinejcf.com/article/S1071-…

🚨 🏨 with HFrEF ⏱️to optimized 4 🏛️ GDMT is the 🔑 determinant of clinical outcomes 🎯Urgency needed 🎯Don’t delay 🎯 No time to wait 🎯Start immediately 🎯Titrate promptly, as tolerated Time to Quadruple GDMT as a Key Performance Measure doi.org/10.1016/j.card…

RCOP has been instrumental in shaping research careers of many in Pakistan. Very pleased to see it being recognised on a global scale as a prospective model for other developing countries European Society of Cardiology Journals

Phenomenal Duke Heart grand rounds by superstar Duke Cardiology Fellows Shahzeb Khan on the prevention of heart failure! #functionnotfailure #heartsuccess Manesh Patel @jennifer_rymer Adam DeVore, MD, MHS Robert Mentz, MD Steve Greene Chet Patel

Khan et al, 2020: Ten‐Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US FDA Approval of Novel Cardiometabolic Drugs Shahzeb Khan Safi U. Khan, MD, MS Izza Shahid Haider Warraich Steve Greene @javedbutler1 Erin D. Michos, M.D. ahajournals.org/doi/10.1161/JA…

Excited for #ACC24? Visit NasirLab Houston Methodist CV prevention team presentations & share ur feedback -Burden, variability and national/health system impact of CV metabolic risk -CV impact of exposome measurements - Insights on Cardiorhum & novel atheromeasurement in gen pop

If you are in Atlanta for #ACC24, join the phenomenal CV prevention team Houston Methodist CV as they present their work and share the latest insights in cardiovascular prevention. Khurram Nasir Sadeer Al-Kindi, MD

Join our team at #ACC24 as we share the latest in CV prevention and cardiometabolic medicine. Khurram Nasir Sadeer Al-Kindi, MD C3PH Houston Methodist CV

Dr. Izza Shahid unveils a poster at #ACC24 highlighting financial toxicity in individuals eligible for semaglutide within a U.S. representative population with established atherosclerotic cardiovascular disease. #MedicalResearch #Cardiology #ASCVD

Dr. Izza Shahid presents at #ACC24 on cost-related medical non-adherence in semaglutide-eligible U.S. adults with atherosclerotic cardiovascular disease, offering insights for the nationally representative population. #MedicalResearch #Cardiology #ASCVD

CVD in women has unique challenges and risk factors needing gender-specific primary prevention strategies. Primary Prevention of CVD in Women - Izza Shahid, Eleonora Avenatti Anoop Titus MD Sadeer Al-Kindi, MD Khurram Nasir Earn free CME! #DeBakeyCVJournal doi.org/10.14797/mdcvj…

Excited to share our article on Obesity and Atherosclerotic Cardiovascular Disease: A Review of Social and Biobehavioral Pathways journal.houstonmethodist.org/articles/10.14… Grateful for Izza Shahid's mentorship!

Thrilled to have presented my poster on T-TEER in Orthotopic Heart Transplant Recipients at #ACC2025! Houston Methodist CV Sachin Goel

Happy to present our abstract on the importance of multimodality imaging in the evaluation and management of paravalvular leaks post-TAVR at #ACC2025. Grateful for all the opportunities and support WilliamZoghbi, and proud to be part of the Houston Methodist CV team!

Initiation and sequencing of guideline-directed medical therapy for heart failure across the ejection fraction spectrum benefits of early up-front initiation of quadruple medical therapy for HFrEF, rapid initiation of SGLT2i for HF regardless of EF link.springer.com/article/10.100…